Eliquis scores DVT/PE recommendation in Europe

Save

Right now, Eliquis, the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto–not to mention the $3-billion-per-year sales forecasts analysts slapped on it in its early days–a new recommendation for expanded use in Europe should give it a boost.